Chemistry:TRV734
From HandWiki
TRV734 is a drug developed by Trevena, Inc. which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G protein signaling pathway over β-arrestin 2 recruitment. It is closely related to oliceridine (TRV130) and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.[1][2] The drug reached phase 2 clinical trials for treatment of pain but was discontinued for this indication.[3][4] It is also under development for treatment of opioid-related disorders, in association with the National Institute on Drug Abuse (NIDA) and having reached phase 1 trials for this use, but no recent development has been reported.[3][4]
See also
- μ-Opioid receptor § Biased agonists
References
- ↑ "A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor". Clinical Pharmacology in Drug Development 9 (2): 256–266. February 2020. doi:10.1002/cpdd.721. PMID 31286645.
- ↑ "Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults". Clin Pharmacol Drug Dev 11 (1): 51–62. January 2022. doi:10.1002/cpdd.1016. PMID 34480428.
- ↑ 3.0 3.1 "TRV 734". 28 March 2025. https://adisinsight.springer.com/drugs/800039874.
- ↑ 4.0 4.1 "Delving into the Latest Updates on TRV-734 with Synapse". 14 October 2025. https://synapse.patsnap.com/drug/4a4db6ea7c924c179b2d8cd038456ff7.
External links
 |  |
